Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorShi, Zhen
dc.contributor.authorWulfkuhle, Julia
dc.contributor.authorNowicka, Malgorzata
dc.contributor.authorGallagher, Rosa Isela
dc.contributor.authorNuciforo, Paolo Giovanni
dc.contributor.authorAntunes de Melo Oliveira, Ana Mafalda
dc.contributor.authorSaura Manich, Cristina
dc.date.accessioned2023-04-17T12:38:46Z
dc.date.available2023-04-17T12:38:46Z
dc.date.issued2022-03-01
dc.identifier.citationShi Z, Wulfkuhle J, Nowicka M, Gallagher RI, Saura C, Nuciforo PG, et al. Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Mar 1;28(5):93–1003.
dc.identifier.issn1557-3265
dc.identifier.urihttps://hdl.handle.net/11351/9351
dc.descriptionBiomarcadors; Càncer de mama triple negatiu
dc.description.sponsorshipThis study was sponsored by F. Hoffmann-La Roche Ltd.
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research
dc.relation.ispartofseriesClinical Cancer Research;28(5)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subjectMama - Càncer - Tractament
dc.subject.meshTriple Negative Breast Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titleFunctional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1158/1078-0432.CCR-21-2498
dc.subject.decsneoplasias de mama triple negativos
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.1158/1078-0432.CCR-21-2498
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Shi Z] Department of Oncology Biomarker, Genentech Inc., South San Francisco, California. [Wulfkuhle J, Gallagher RI] Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia. [Nowicka M] F. Hoffmann-La Roche Ltd, Basel, Switzerland. [Saura C, Oliveira M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Nuciforo PG] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid34907082
dc.identifier.wos000767267300001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Portada del document
Portada del document
Portada del document
Portada del document
Portada del document
Portada del document
Portada del document
Portada del document
Portada del document
Portada del document
Portada del document
Portada del document
Portada del document
Portada del document

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple